- Home
- SLNO vs GOF Comparison
SLNO vs GOF Comparison
Compare SLNO & GOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLNO | GOF |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | 2014 | 2006 |
Fundamental Metrics
Financial Performance| Metric | SLNO | GOF |
|---|---|---|
| Price | $52.95 | $11.51 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $83.00 | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 1.1M |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 108.90 | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $1,450,788.00 | N/A |
| Revenue This Year | $150.46 | N/A |
| Revenue Next Year | $50.37 | N/A |
| P/E Ratio | $135.77 | ★ N/A |
| Revenue Growth | ★ 138.82 | N/A |
| 52 Week Low | $29.43 | $10.54 |
| 52 Week High | $89.12 | $15.20 |
Technical Indicators
Market Signals| Indicator | SLNO | GOF |
|---|---|---|
| Relative Strength Index (RSI) | 77.35 | 56.68 |
| Support Level | $48.91 | $11.20 |
| Resistance Level | $55.47 | $12.50 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | -0.57 | 0.02 |
| Stochastic Oscillator | 96.43 | 71.26 |
Price Performance
Historical ComparisonAbout SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.